Global Colorectal Cancer Forecast and Market Analysis 2017-2036: Avastin will Remain the Leading Targeted Therapy

By , in PR PR World on .

Colorectal cancer (CRC) is one of the “big four” tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Market Snapshot

  • Avastin will remain the leading targeted therapy in the colorectal cancer market through to 2024.
  • Avastin in combination with FOLFOX remains the most commonly prescribed first-line treatment for Stage IV disease.
  • As screening has not yet affected incidence rates, incident cases are predicted to increase between 2016 and 2036.
  • Approved drugs seek label expansions to better compete as patent expiries threaten to erode branded sales of Avastin and Erbitux.
  • Pipeline candidates will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market.

Key Topics Covered:

Forecast: Colorectal Cancer In The Us, Japan, And 5EU

  • Executive Summary
  • Recent Forecast Updates
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Avastin
  • Product Profile (Late Stage): Cotellic
  • Product Profile: Cyramza
  • Product Profile: Erbitux
  • Product Profile: Keytruda
  • Product Profile: Lonsurf
  • Product Profile (Late Stage): Oncovax
  • Product Profile: Opdivo
  • Product Profile: Stivarga
  • Product Profile: Ts-1
  • Product Profile (Late Stage): Tecentriq
  • Product Profile: Vectibix
  • Product Profile: Zaltrap
  • Product Profile (Late Stage): Binimetinib
  • Product Profile (Late Stage): Lefitolimod
  • Product Profile (Late Stage): Masitinib
  • Product Profile (Late Stage): Napabucasin

Treatment: Colorectal Cancer In The Us, Japan, And 5EU

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

Epidemiology: Colorectal Cancer In The Us, Japan, And 5EU

  • Executive Summary
  • Disease Background
  • Sources And Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths And Limitations
  • Appendix: Additional Sources

Marketed Drugs: Colorectal Cancer

  • Executive Summary
  • Product Overview
  • Product Profile: Avastin
  • Product Profile: Cyramza
  • Product Profile: Erbitux
  • Product Profile: Keytruda
  • Product Profile: Lonsurf
  • Product Profile: Opdivo
  • Product Profile: Stivarga
  • Product Profile: Ts-1
  • Product Profile: Vectibix
  • Product Profile: Zaltrap

Pipeline: Colorectal Cancer

  • Executive Summary
  • Clinical Pipeline Overview
  • Product Profile (Late Stage): Cotellic
  • Product Profile (Late Stage): Oncovax
  • Product Profile (Late Stage): Tecentriq
  • Product Profile (Late Stage): Binimetinib
  • Product Profile (Late Stage): Encorafenib
  • Product Profile (Late Stage): Lefitolimod
  • Product Profile (Late Stage): Masitinib
  • Product Profile (Late Stage): Napabucasin

For more information about this report visit https://www.researchandmarkets.com/research/tjfb6k/global_colorectal?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-colorectal-cancer-forecast-and-market-analysis-2017-2036-avastin-will-remain-the-leading-targeted-therapy-300599383.html

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

The following two tabs change content below.
Jasmine Petters

Jasmine Petters

Jasmine hails from the city of Nizams, Hyderabad, and is currently pursuing her M.D. from there only. She is an internet wizard and has keen passion in All Things tech. She is a regular Comment contributor for The Daily Telescope and writes a Web column, in which she covers war, sports, and everything in between.
%d bloggers like this: